PEOPLE - CytoCore makes appointment:
This article was originally published in Clinica
Augusto Ocana has been appointed CEO for US cancer screening systems company CytoCore (Chicago, Illinois), succeeding Dr David Weissberg. On the eve of the international launch of its new product, the e2Collector (Pap smear device), the company will leverage Dr Ocana's expertise in market distribution, strategic partnering, financing and business development. Previous positions held by Dr Ocana include senior vice-president and managing director at CH-Werfen (Barcelona), a healthcare group that manufactures and distributes diagnostics, medical devices and scientific instruments.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.